Dell Backs Cancer Diagnosis Startup Ibex
Ibex develops an AI-driven diagnostic system using data from digitized glass slides and electronic medical records to reveal cancer diagnoses for tissue biopsies
08:0819.03.19
Dell, through its tech investment arm Dell Technologies Capital, has participated in a funding round for Tel Aviv-based cancer diagnosis startup Ibex Medical Analytics Ltd., the latter announced Tuesday. The $11 million round was led by Israel-based venture capital fund aMoon.
Ibex co-founders, chief medical officer and chief strategy officer. Photo: PR The company’s product for prostate core needle biopsies was clinically deployed throughout Israel last year as part of a partnership with local health maintenance organization (HMO) Maccabi Healthcare Services. The company intends to begin marketing it to pathology labs internationally, according to the company’s statement.
For daily updates, subscribe to our newsletter by clicking here.
Founded in 2016, Ibex develops a diagnostic system that uses computer vision, machine learning, and electronic medical records to confirm cancer diagnoses of tissue biopsies. Ibex’s technology does not replace the doctor, it just gives another opinion that can minimize the risk of human error, Ibex co-founder and CEO Joseph Mossel, said in a phone interview with Calcalist Sunday. “It is like an insurance policy that helps doctors sleep at night,” he added.
Ibex co-founders, chief medical officer and chief strategy officer. Photo: PR Using the secured funding, the company also intends to expand its diagnostic offering to additional types of cancer, including breast cancer and gastrointestinal cancer.
